Adtran unveils compact 10G precision timing solution for edge networks
News summary: New OSA 5410XG meets demand for reliable edge synchronization and enhanced efficiency in high-bandwidth environments Latest addition to Adtran’s Oscilloquartz portfolio is a PTP grandmaster for edge deployment with 10G interfaces and real-time sync monitoring Compact, robust solution with programmable I/O and support for all relevant PTP profiles offers precise timing for any mission-critical PNT network
Adtran today launched the OSA 5410XG, the latest addition to its Oscilloquartz portfolio of precision timing solutions. Building on the success of the widely adopted OSA 5410, this next-generation product is the first in the Oscilloquartz family of PTP grandmaster devices designed specifically for edge network deployment. The compact and highly reliable solution supports 10Gbit/s interfaces, meeting the timing demands of modern high-bandwidth networks. Featuring Syncjack™ technology for real-time synchronization monitoring, the OSA 5410XG helps maintain assured positioning, navigation and timing (PNT) by detecting and resolving sync issues before they impact services. It will benefit a wide range of industries, such as telecom, where precise timing is critical for 5G; power utilities modernizing smart grids; broadcasters managing live content distribution; and the defense sector, which requires secure and reliable communication.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910449506/en/
Adtran’s OSA 5410XG has been specifically engineered to deliver ultra-reliable synchronization at the edge of the network. (Photo: Business Wire)
“The demand for efficient, reliable and low-cost synchronization at the network’s edge has never been greater. Edge timing devices must be compact, robust and capable of handling high-bandwidth requirements to ensure optimal performance. Supporting 10Gbit/s data rates is also crucial for accurately maintaining high-speed transmission and network efficiency. That’s why we engineered the OSA 5410XG. With advanced 10Gbit/s interfaces, it meets the needs of even the most demanding network environments, from enabling 5G rollouts in telecom to supporting smart grids, secure defense communications and real-time broadcasting,” said Gil Biran, GM of Oscilloquartz, Adtran. “Purpose-built for edge applications, the OSA 5410XG offers exceptional performance and reliability, making it an ideal choice compared to more expensive and complex options.”
With advanced features to meet the complex demands of modern networks, the OSA 5410XG is ideal for a broad range of industries. It supports IRIG interfaces, accommodates various power profiles and measurements, and offers a comprehensive range of PTP profiles. These capabilities are essential for industries transitioning from legacy time distribution methods to modern packet-based synchronization. Its advanced Syncjack™ technology provides superior timing distribution, monitoring and assurance. Additionally, the OSA 5410XG includes robust jamming and spoofing detection capabilities to maintain secure and reliable timing. The device also features an alarm relay and multiple power supply options, enhancing its flexibility and adaptability to various applications. These features make it particularly valuable for power utilities, telecom operators, defense and the finance sector, where precise timing is crucial for transaction timestamping and regulatory compliance.
“The OSA 5410XG’s compact and cost-effective small form factor is optimized for access network deployment, making it easy to deploy and manage. As a small, cost-effective PTP grandmaster and Class D boundary clock, it’s designed to provide superior synchronization with minimal footprint. Equipped with multiple SFP+ 10Gbit/s ports, enhanced phase and frequency synchronization, and jamming and spoofing detection capabilities, it also provides robust security and performance,” commented Igal Pinhasov, VP of product line management at Oscilloquartz, Adtran. “Designed with future-proofing in mind, the OSA 5410XG is fully compatible with evolving PNT standards. Its versatility delivers the operational simplicity and efficiency that our customers demand. This ensures that the OSA 5410XG will remain a vital component of timing network infrastructure for years to come.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910449506/en/
Contacts
For media
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.comFor investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom